用ocrelizumab治疗的复发性多发性硬化症患者的渐进性多焦点白内障:一个病例报告
Marc Puig-Casadevall1, Gary Álvarez-Bravo1,2, Ana Quiroga Varela2,3
1Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Salt, Spain.
European journal of neurology
|July 24, 2023
概括
渐进性多焦点白内障 (PML) 是多发性硬化症治疗的罕见并发症. 这份病例报告详细介绍了一名患有复发性缓解性多发性硬化症的患者,他在接受奥克雷利祖马布治疗期间患上PML.
科学领域:
- 神经免疫学 神经免疫学
- 神经学 神经学
- 临床医学 临床医学
背景情况:
- 渐进性多焦点白内障 (PML) 是一种罕见的,往往致命的,机遇性脑部感染.
- PML是某些多发性硬化症 (MS) 治疗的已知并发症,特别是natalizumab.
- 越来越多地报告了PML与其他免疫抑制疗法 (包括ocrelizumab) 发生的情况.
研究的目的:
- 在患有复发性缓解性多发性硬化症的患者中报告PML病例.
- 描述一个用ocrelizumab治疗的患者PML的发展.
- 在现有文献和病理生理学背景下讨论此案.
主要方法:
- 案例报告的呈现方式.
- 对临床表现和疾病进程的审查.
- 关于PML和ocrelizumab的文献评论.
主要成果:
- 一名患有复发性复发性多发性硬化症的患者患有PML.
- 该患者接受了ocrelizumab治疗,并且之前没有接触过natalizumab.
- 总结了病例表现和疾病过程.
结论:
- 与其他免疫抑制疗法一样,ocrelizumab可能与MS患者的PML发展有关.
- 了解PML的病理生理学和风险因素对于患者的安全至关重要.
- 需要进一步的研究,以充分阐明新型多发性硬化疗法对PML的风险.
相关概念视频
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Open Angle Glaucoma: Treatment
481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Angle Closure Glaucoma: Treatment
565
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
565
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Disorders of Leukocytes
983
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
983


